AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03617133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Systemic application of simultaneous chemotherapy
Description: According to international standard and evidence, simultaneous chemotherapy (CHT) (min. 5x40 mg/m2 cis Platinum) was prescribed in the EMBRACE protocol for all patients, who qualify for its administration. Certain rules were given for adaption according to international guidelines. 90-95% of EMBRACE patients received simultaneous CHT. Most of the EMBRACE cohort is consecutive patients representing the cervix cancer patient population in the respective centers. About 70% of patients received ≥5 cycles, while 30% received 0-4 cycles. CHT has impact on systemic control, which is pronounced in high risk patients (node positive and/or stage III/IV) with a 20% difference in systemic recurrence. A center effect has been found in the ability to administer chemotherapy with 15-85% of the patients receiving ≥5 cycles of CHT. To reach optimal outcome, particularly in the high risk group, the EMBRACEII protocol also focusses on appropriate administration of CHT following international guidelines.
Study NCT03617133 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reduction of overall treatment time
Description: Several studies indicate that maintaining an overall treatment time (OTT) of \<=50 days is important for local control. RetroEMBRACE data confirms that OTT remains of importance in the realm of IGABT. As there is significant variation of OTT across patients and institutions in retroEMBRACE, the EMBRACEII study aims to reduce the OTT so that the majority of patients (>80%) will adhere to the \<=50 day threshold. The measures to reduce OTT in EMBRACE is to systematically apply 25 fractions of EBRT including lymph node boost, and furthermore to carefully plan the BT schedule, so that brachytherapy is delivered towards the end of EBRT and/or directly after EBRT.
Study NCT00218855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: thalidomide
Description: tablets thalidomide start 100 mg x 2 escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. The same procedure is repeated by first relapse.
Study NCT00218855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thalidomide
Description: tablets thalidomide start 100 mg x 2 escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. The same procedure is repeated by first relapse.
Study NCT00218855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100 mg x 2 mg tablets escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. This procedure is repeated by first relapse.
Study NCT00218855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: 100 mg x 2 mg tablets escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. This procedure is repeated by first relapse.
Study NCT01132677 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hylan G-F 20 (Synvisc One)
Description: Single IA injection of 6cc's. Injections will be administered as outlined on the company label.
Study NCT01132677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone (Corticosteroid)
Description: Single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label.
Study NCT01350960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPC5001
Description: 3 weekly SC injections
Study NCT01350960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: 3 weekly SC injections
Study NCT00868192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study NCT00868192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT02520856 — intervention group
Intervention type: OTHER
Intervention: blood sample
Study NCT00271700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Order Set, Education, Feedback
Study NCT01181375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumour Biopsies and Blood Sampling
Description: Patients who consent to the tissue part of this study will have Biopsies taken for study purposes at the same time as their routine tumour biopsies . In addition,those who consent to the blood sampling part of the study will have their samples taken assess serum biomarkers of tumour oxygenation.
Study NCT02881086 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cranial irradiation
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Idarubicin
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mercaptopurine
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: VP16
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Daunorubicin (DNR)
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study NCT04339738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04339738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04339738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02918071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab administered subcutaneously every 4 weeks
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT03496649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dysport 500 Unit Powder for Injection
Description: Dysport administered by intramuscular injection
Study NCT00662324 — intervention group
Intervention type: BEHAVIORAL
Intervention: focus groups
Description: Focus group with MSKCC patients with lung, breast and prostate cancer who have taken part in clinical trials and other caregivers. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would have been useful to the patient you care for in his/her experience in a clinical trial.~The focus group to last from 60 to 90 minutes.
Study NCT00662324 — intervention group
Intervention type: BEHAVIORAL
Intervention: focus groups
Description: Focus group with MSKCC patients with lung, breast and prostate cancer who have not taken part in clinical trials and other caregivers. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful if the patient you care for were ever to take part in a clinical trial sometime in the future.~We expect the focus group to last from 60 to 90 minutes.
Study NCT00662324 — intervention group
Intervention type: BEHAVIORAL
Intervention: focus groups
Description: MSKCC clinicians who work with lung, breast and prostate cancer patients. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful to your patients who take part in clinical trials.~Expect the focus group to last from 60 to 90 minutes.
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Study NCT03031262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
Study NCT02881086 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem cell transplantation
Study NCT02881086 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem cell transplantation
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Study NCT03031262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
Study NCT03031262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide at a dose of 20mg/d twice a week for 3 months.
Study NCT00502372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Supplement/Amino acids and HMB
Description: Subjects will be randomized to receive enriched dietary supplement (Juven) v arginine only (Argenaid) dietary supplement
Study NCT00502372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement/Amino acids and HMB
Description: Subjects will be randomized to receive enriched dietary supplement (Juven) v arginine only (Argenaid) dietary supplement
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vindesine
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adriamycin
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Study NCT00298740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aventis U-400 Insulin
Study NCT03235609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl used with propofol for sedation
Study NCT03235609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine used with propofol for sedation
Study NCT03439579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home weight loss program
Description: Patient remote self-monitoring of diet, activity, and weight with clinician feedback provided remotely based on self-monitored data.
Study NCT01526460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 80 mg
Study NCT01526460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 40 mg
Study NCT01526460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no statin loading dose
Study NCT03519282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A multifocal toric lens
Description: contact lens
Study NCT03519282 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A multifocal toric lens
Description: contact lens
Study NCT03519282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A Multifocal Toric Lens
Description: contact lens
Study NCT03519282 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A Multifocal Toric Lens
Description: contact lens
Study NCT00502372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Juven
Description: comparison of Juven with arginine only product in wound healing
Study NCT00502372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juven
Description: comparison of Juven with arginine only product in wound healing
Study NCT03590288 — intervention group
Intervention type: PROCEDURE
Intervention: Transjugular intrahepatic portosystemic shunt
Description: Covered stents will be used, that will be dilated to 8 mm. The aim will be to reduce the portacaval pressure gradient (PPG) below to 25-75% of baseline. Not paralleled TIPS or over-dilatation are allowed.~Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of big portosystemic collaterals feeding the varices.~After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted.~Measurement of portacaval pressure gradient will be done immediate after TIPS, then repeated 1-3 days and at 1 month after the procedure.~A TIPS revision will be performed once shunt dysfunction is suspected.
Study NCT03015454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Severe Sepsis Prediction
Description: Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
Study NCT00672776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Study NCT00672776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04339738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04339738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02305186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered at a dose of 200 mg IV every 3 weeks on days 1, 22, and 43 during concurrent neoadjuvant chemoradiation treatment
Study NCT02305186 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant Chemoradiation
Description: Chemoradiation with capecitabine (825 mg/m2 orally twice daily, Monday through Friday, on days of radiation only) and radiation (50.4 Gy in 28 fractions over 28 days)
Study NCT03968497 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Postoperative pain assessment with female investigator
Description: Postoperative pain evaluation by a female investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
Study NCT02305186 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiation
Description: Chemoradiation with capecitabine (825 mg/m2 orally twice daily, Monday through Friday, on days of radiation only) and radiation (50.4 Gy in 28 fractions over 28 days)
Study NCT02604511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study NCT00267930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernakalant (oral)
Study NCT00267930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Study NCT03015454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Severe Sepsis Detection
Description: Upon receiving information from the severe sepsis detector in the UCSF electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
Study NCT03015454 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Severe Sepsis Detection
Description: Upon receiving information from the severe sepsis detector in the UCSF electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
Study NCT02964429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diacap Pro High-Flux
Description: During dialysis treatment ultrafiltration rate will be changed following a fixed schedule and resulting changes in Transmembrane Pressure (TMP) recorded to generate data for calculation of the in-vivo KUF.
Study NCT01231113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artesunate-amodiaquine
Description: The 452 pregnant women in this arm will receive artesunate-amodiaquine tablets(artesunate 4mg/kg and amodiaquine 10mg/kg in twelve hourly doses over 3 days
Study NCT01231113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: a fixed-dose combination to be administered to the other 452 pregnant women in this arm at an estimated total dosing of 6.75mg/kg dihydroartemisinin and 55mg/kg piperaquine over 3 days
Study NCT03368378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early DVC ligation
Description: After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. This approach would allow for the preservation of the external urethral sphincter and for the identification and preservation of the neurovascular bundles that are located in the anterolateral aspect of the prostate. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
Study NCT03368378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early DVC ligation
Description: After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. This approach would allow for the preservation of the external urethral sphincter and for the identification and preservation of the neurovascular bundles that are located in the anterolateral aspect of the prostate. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
Study NCT02562352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAPER program
Description: Patients will be randomized to receive the TAPER program at study start or delayed intervention at 6 months.
Study NCT02507336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100-300 mg capsule taken by mouth once daily.
Study NCT02528097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
Study NCT02528097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: 25% salt poor albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 or later only to those individuals with renal insufficiency and risk for renal failure (Cr > 1.0 or BUN or Cr > baseline)
Study NCT00536978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA-C
Description: 100 mg/m\^2 IV Daily Over 1 Hour for 4 Days
Study NCT00536978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: 300 mg/m\^2 IV Over 1 Hour for 1 Day
Study NCT00536978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: 15 mg IV Daily Over 30 Minutes for 3 Days
Study NCT00536978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1000 mg/m\^2 IV Daily Over 1 Hour for 3 Days
Study NCT00536978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m\^2 IV Daily Over 3 Hours for 4 Days
Study NCT00536978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 IV Daily Over 1 Hour for 3 Days
Study NCT00536978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 100 mg/m\^2 IV Over 30 Minutes for 1 Day.
Study NCT00536978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m\^2 IV Over 5-7 Hours Weekly for 3 Weeks.
Study NCT00536978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplantation
Description: Stem Cell Infusion on Day 0.
Study NCT00536978 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body radiation (TBI)
Description: TBI on Day 5 following chemotherapy, before stem cell infusion.
Study NCT00536978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5 mg/m2 IV on Days +1, +3, and +6.
Study NCT00536978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.03 mg/kg/day IV starting on Day -2, to be given through day 60, tapered by 20% every week, then discontinue by day 90.
Study NCT00536978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adback NK or T Cell
Description: Adback natural killer (NK) cells or T cells after transplantation to enhance full engraftment of donor cells. Cell adback after transplantation applies only if there is no active GVHD, and no previous episode of grade II-IV GVHD.